Labcorp (LH) Stock
Large clinical lab serving hospitals and drug developers. Here's the price, business snapshot, and what's worth knowing about Labcorp in July 2026.
Laboratory Corp. of America Holdings (LabCorp, ticker LH) is a large clinical diagnostics and healthcare services company providing laboratory testing, diagnostic information, and drug development services to hospitals, physicians and biopharma clients. With a market capitalisation of about $23.6bn, LabCorp earns revenue from fee-for-service testing, contracts with healthcare providers, and outsourced clinical trial services. Key investor considerations include steady structural demand for diagnostics from an ageing population and growing use of personalised medicine, balanced against sensitivity to reimbursement rates, regulatory change and competition. LabCorp’s results can be cyclical—volumes often fluctuate with public-health trends such as respiratory outbreaks—and capital allocation choices and acquisitions affect near-term profitability. Investors should review recent financials, margins, cash flow and valuation, and consider exposure to healthcare reimbursement risk. This information is educational only and not personal financial advice; investors should assess suitability and consult a professional before acting.
Why It’s Moving
Analysts reaffirm bullish stance on LH in 2026, citing strong pharmaceutical margins and consistent earnings as key upside drivers.
- Wall Street analysts maintain a consensus 'Buy' rating, projecting potential upside of approximately 22% over the next 12 months based on current valuations.
- The positive outlook reflects Labcorp's ability to outperform market expectations through its diversified portfolio of testing services and pharmaceutical R&D partnerships.
- Investors are reacting to the stability of the healthcare sector, where consistent cash flows and long-term contracts are shielding stocks from recent macroeconomic volatility.
Analysts reaffirm bullish stance on LH in 2026, citing strong pharmaceutical margins and consistent earnings as key upside drivers.
- Wall Street analysts maintain a consensus 'Buy' rating, projecting potential upside of approximately 22% over the next 12 months based on current valuations.
- The positive outlook reflects Labcorp's ability to outperform market expectations through its diversified portfolio of testing services and pharmaceutical R&D partnerships.
- Investors are reacting to the stability of the healthcare sector, where consistent cash flows and long-term contracts are shielding stocks from recent macroeconomic volatility.
When is the next earnings date for LABCORP HOLDINGS INC (LH)?
Based on Labcorp's historical reporting schedule, the next earnings release is estimated to occur on July 23, 2026, though the company has not yet confirmed an official date. This upcoming report will cover the financial results for the second quarter of 2026, ending June 30, 2026. Analysts generally project an earnings per share of approximately $4.79 for this quarter, reflecting continued operational strength. Please note that while this date is a reliable estimate, investors should verify the official announcement as the company may adjust its schedule.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Laboratory Corp. of America Holdings stock, expecting its value to rise.
Financial Health
Laboratory Corp. is performing well with solid profits, cash flow, and revenue generation.
Dividend
Laboratory Corp. of America Holdings has a low dividend yield of 1.14%, making it less attractive for dividend-focused investors. If you invested $1000 you would be paid $11.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
CHEMED CORP
Provides hospice and palliative care services to patients facing life-limiting illness
ALIGNMENT HEALTHCARE INC
Alignment Healthcare, Inc. is a consumer-centric platform designed to improve the healthcare experience for seniors. The Company’s operations primarily consist of Medicare Advantage Plans in the states of California, North Carolina, Nevada, Arizona, Florida and Texas. It partners with local providers to deliver coordinated care, powered by its customized care model, 24/7 concierge care team and purpose-built technology (AVA). AVA’s capabilities include consumer experience, internal care delivery, external providers, health plan operations and growth operations. AVA offers a digital ecosystem that enables its members and their support system to get the information and care they need, when and how they need it. With their AVA-powered member portal and mobile app, seniors have many self-service capabilities and can get 24/7 care, send secure messages to their concierge and care teams, check their rewards and ACCESS On-Demand Concierge Card balance, and view their health history.
Brookdale
A leading owner and operator of senior living communities in the United States.
Baskets Featuring LH
Personal Care Safety: Could Talc Verdict Boost Stocks?
A record $1.5 billion verdict against Johnson & Johnson in a talc cancer case highlights the immense legal and financial risks associated with certain consumer product ingredients. This creates a compelling investment opportunity in companies that provide safer, alternative materials and advanced testing services for the personal care industry.
Published: 24 December 2025
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketRiding The Regulatory Wave In Healthcare
The Department of Justice's investigation into UnitedHealth's Medicare billing practices has cast a shadow over the health insurance industry, potentially leading to stricter oversight. This creates an investment opportunity in companies that provide compliance and auditing services, which are essential for navigating a more complex regulatory environment.
Published: 25 July 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: 15 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diagnostics demand trends
Ageing populations and personalised medicine support long-term demand for testing, though volumes can fluctuate with public-health events and policy changes.
Global service footprint
A broad geographic presence and biopharma contracts diversify revenue, but differing regulations and reimbursement rules across markets add complexity.
Innovation and services
Investments in technology and clinical-trial services may improve margins over time, although competition and pricing pressure can constrain gains.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
